Drugs and the older person by Kalula, SZ
Persons aged 60 years and over are the main consumers of drugs 
because of increased pathology requiring multiple medications. 
No local data are available but USA data show that while older 
persons constitute 13% of that country’s total population, they 
consume approximately 35% of all medications used.1 Ageing 
alters pharmacokinetics (absorption, distribution, metabolism and 
elimination) and pharmacodynamics (drug-receptor or drug-organ 
interactions), which affects choice, dose and dosing frequency of 
many drugs. Pharmacological and non-pharmacological factors 
associated with ageing predispose older persons to an increased risk 
of adverse drug events. Knowledge of drug therapeutics is based on 
studies in younger people, as older persons are largely excluded 
from drug trials; adverse drug events in the older population are 
therefore only identified in the post-marketing phase. Adverse 
drug events are observed 2 - 3 times more frequently in older than 
in younger adults2 and account for 5 - 17% of hospital admissions 
in this age group.3
Age-associated mechanisms of altered 
drug effects
Changes in pharmacokinetics and pharmacodynamics that occur 
with age result from changes in physiological function. In addition, 
multiple chronic diseases and consequent polypharmacy increase 
drug-drug and drug-disease interactions.4 Changes in homeostasis 
such as decreased plasma volume and thirst mechanism, 
diminished vasomotor regulation and impaired glucose tolerance 
decrease compensatory mechanisms and increase susceptibility to 
adverse drug reactions.5
Drug absorption
Age-related changes lead to a decrease in small-bowel surface area 
and an increase in gastric pH, but these changes do not lead to 
clinically significant changes in drug absorption.6 Factors affecting 
drug absorption include patients’ comorbid illnesses, timing 
of drug administration and other accompanying products. An 
increase in gastric pH from proton pump inhibitors or antacids may 
decrease absorption of certain drugs, such as imidazole antifungals 
and ampicillin, and increase the absorption of nifedipine and 
amoxycillin.7,8 Most drugs are absorbed from the gastrointestinal 
tract by simple diffusion and there are no age-related changes 
in the absorption of these drugs. Drugs absorbed into the blood 
stream via active transport mechanisms (iron, calcium, magnesium 
and vitamin B12) are poorly absorbed in the elderly.9 Intestinal 
metabolism and active extrusion of absorbed drugs have recently 
been recognised as a major determinant of oral drug availability and 
contribute to poor oral bioavailability of certain drugs. Cytochrome 
P450 (CYP) 3A, the major phase I drug metabolism enzyme and 
a multi-drug efflux pump, P-glycoprotein, are present at high 
levels in small-intestinal enterocytes.10 These proteins are induced 
or inhibited by many compounds. P-glycoprotein inhibitors, e.g. 
ketoconazole and atorvastatin, increase bioavailability of digoxin, 
and administration of rifampicin, a potent inducer of CYP3A and 
P-glycoprotein, decreases the bioavailability of cyclosporin and 
nifedipine.10 
Drug distribution
Ageing results in changes in body composition with increased 
adipose tissue and decreased total body water and lean body mass. 
These changes lead to an increased volume of distribution of lipid-
soluble drugs. Thus, lipid-soluble drugs, e.g. chlordiazepoxide, 
diazepam, amiodarone and verapamil, are excreted from the body 
at a slower rate, prolonging the half-life,8,11 and taking longer to 
reach a steady-state concentration, i.e. the amount of drug entering 
the system being equal to the amount being eliminated. Water-
soluble drugs, e.g. cimetidine, digoxin, ethanol and lithium, have 
a decreased volume of distribution, leading to a higher plasma 
concentration. Certain drugs bind to plasma proteins and their 
pharmacological effect is determined by the unbound proportion 
of the drug. Poor nutrition, chronic illness and debility lead to 
decreased serum albumin.12 Highly protein-bound drugs, e.g. 
warfarin, non-steroidal anti-inflammatory drugs (NSAIDs), 
phenytoin, valproic acid, diazepam, lorazepam, calcium channel 
blockers and proton pump inhibitors have elevated free and 
pharmacologically active drug concentrations, leading to a higher 
incidence of drug toxicity.1,8,11
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The liver is primarily responsible for 
drug metabolism and the kidney for drug 
excretion, but metabolism can also take place 
in the intestinal wall, lungs, skin, kidneys 
and other organs. Age-related changes lead 
to decreased liver size, hepatic blood flow 
and enzyme activity.13 A decrease in hepatic 
blood flow prolongs the duration of effect 
in drugs that undergo extensive first pass 
metabolism, e.g. propranolol, theophylline, 
tricyclic antidepressants, verapamil and 
nitrates – less drug is extracted, increasing 
bioavailability.7 Drug metabolism occurs 
either through phase I reactions: oxidation, 
reduction, hydroxylation, dealkylation and 
hydrolysis, which are mediated through the 
cytochrome P450 (CYP450) enzyme system 
or phase II reactions. Cytochrome P450 
enzymes are found primarily in hepatocytes 
and cells of the wall of the gut. The phase 1 
drug metabolism pathway, which leads to 
biotransformation of a drug to a more polar 
product for excretion, is decreased in elderly 
persons, increasing free drug concentrations 
and potential toxicity. Examples of drugs that 
undergo phase I metabolism are diazepam, 
chlordiazepoxide, codeine, diphenydramine 
and warfarin.2,11 Drugs that either inhibit or 
induce this enzyme system may predispose 
to drug interactions with toxicity or under-
treatment. Phase II reactions, unaffected by 
age-related changes, involve conjugation of 
drugs through glucuronidation, acetylation 
or sulphation; examples of drugs that 
undergo phase II metabolism are lorazepam 
and oxazepam.6
Drug excretion
Most drugs are eliminated by the kidney 
as either the parent compound or as a 
metabolite or metabolites. Glomerular 
filtration declines as a consequence of a 
decrease in renal blood flow and kidney size 
and a decrease in functioning nephrons.7 
Serum creatinine in an older person is not 
an accurate reflection of renal function. 
An older person’s production of creatinine 
is reduced due to a decline in lean muscle 
mass.8 Measurement of 24-hour creatinine 
clearance would be the most accurate way of 
determining the dosage of renally excreted 
drugs, but is time consuming and requires 
an accurate 24-hour urine collection. The 
Cockroft and Gault equation, although it 
has limitations, can be used to estimate a 
patient’s creatinine clearance in the absence 
of renal failure:
Creatinine clearance (ml/min) = 
(140 − age) × body weight (kg)
0.82 × serum creatinine (μmol/l)
 
For females, multiply serum 
creatinine by 0.85 instead of 0.82.
Renal excretion of drugs depends on 
glomerular filtration rate (GFR). GFR 
decreases by 10% per decade from the 
age of 30, though these changes are not 
universal. With ageing, both glomerular 
filtration and tubular secretion of drugs are 
reduced. Elimination of a drug is affected 
by reduction in renal function if 60% of the 
drug is renally excreted.5 Renally excreted 
drugs, e.g. allopurinol, aminoglycosides, 
penicillin, atenolol, sotalol, angiotensin-
converting enzyme (ACE) inhibitors, 
digoxin, H2 blockers, lithium, metformin, 
require dose adjustment and monitoring.11 
Toxicity may also result from combining 
two drugs that compete for renal secretion, 
e.g. probenicid and penicillin. Serum drug 
levels may be used to monitor certain drugs 
but drug levels within therapeutic range, e.g. 
toxicity of digoxin, do not exclude clinical 
toxicity.
Pharmacodynamics
The pharmacodynamic action of a drug is the 
length and intensity of its pharmacological 
effect on target cells. In older patients, changes 
in drug-receptor or drug-organ interactions 
cause changes in drug effect. Ageing causes 
many receptors to function less efficiently and 
reduces the density of beta receptors, leading 
to toxic reactions from beta blockers, such as 
propranolol and diminished response to β2-
agonists, such as salbutamol.8,11 A decline in 
parasympathetic control increases the effects 
of anticholinergics, e.g. urinary retention, 
blurring vision and constipation. A reduction 
in brain receptors, an increase in blood-
brain barrier permeability and a decrease in 
cerebral blood flow increase brain sensitivity 
to drugs; delirium, sedation, depression and 
confusion are commonly associated with 
anticholinergics, antidepressants, analgesics, 
neuroleptics, digoxin and anticonvulsants.2,11 
In addition, a progressive reduction in 
homeostatic mechanisms predisposes the 
elderly to toxic reactions, e.g. postural 
hypotension in response to drugs that lower 
arterial blood pressure.2 Advanced age is a risk 
factor for developing sulphonylurea-induced 
hypoglycaemia because of impairment of 
glucose counter-regulation.2
Polypharmacy 
The balance between therapeutic gain and 
risk becomes critical in the elderly. Drug-
drug interactions increase exponentially with 
the number of drugs used. Polypharmacy 
provides an opportunity not only for 
drug-drug interactions but also drug-
disease interactions.14 Examples of drug-
disease interactions are anticholinergic 
drugs (amitriptyline, clomipramine and 
dothiepin), which exacerbate glaucoma, 
benign prostatic hyperplasia, dementia 
and xerostomia (dry eyes), and NSAIDs, 
which exacerbate hypertension and cardiac 
failure.11 The presentation of adverse drug 
events is nonspecific, which increases a 
tendency to treat adverse events with other 
drugs.
Under-prescribing of beneficial medications 
to older adults is equally prevalent. Under-
prescribing may result from avoidance of 
over-prescribing, adverse effects or complex 
medication regimens, as well as from a 
belief that older adults will not benefit 
from medications intended as primary or 
secondary prevention or from aggressive 
management of chronic conditions such 
as hypertension or diabetes mellitus. 
Commonly under-prescribed medications 
include ACE-inhibitors and β-blockers for 
heart failure, aspirin following an acute 
myocardial infarction, warfarin for atrial 
fibrillation, statins for primary prevention 
of cardiac events, and narcotic analgesics for 
pain control.7
Adverse drug events
An adverse drug event is defined as an 
injury resulting from the use of a drug at 
usual doses. While some drug reactions are 
idiosyncratic (type B reactions) and thus 
unpredictable, 65 - 70% occur because of 
known pharmacological effects (type A 
reactions) and are mostly avoidable. Adverse 
drug reactions have been estimated to 
account for 7.9 - 24% of all hospitalisations 
of elderly patients.3 Risk factors for adverse 
drug events are listed in Table I. Table II 
shows common modes of presentation of 
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Guidelines for effective prescribing
The following precautions are required for 
the administration of drugs to older patients 
in order to avoid over-prescribing:11 
•   Obtain a complete drug history
•    Use non-drug treatment whenever 
possible
•    Use no drug before its time and no drug 
beyond its time – always review the need 
to continue medications
•   Know the drugs you use
•   Start low, go slow
•   Treat adequately
•   Encourage treatment adherence
•   Use new drugs with particular caution. 
Compliance
Non-compliance with a drug regimen 
can inhibit therapeutic response and 
successful treatment. Physical and cognitive 
impairment may prevent older patients from 
complying with their drug regimens. It is 
essential that a patient/caregiver understands 
why a drug is important and how to take it. 
Compliance with long-term medication is 
especially poor as patients are not acutely ill 
and may not see a need for continued drug 
therapy. Compliance is affected by many 
factors but can be improved. Table III shows 
factors predisposing to non-adherence to 
treatment.
Poor compliance may be reduced by:
•   simplifying drug regimens
•   avoiding polypharmacy
•    educating the patient and providing 
carefully written instructions 
•    warning the patient of common adverse 
drug reactions
•    performance of cognitive and physical 
assessments
•    encouraging face-to-face review. 
Challenges to 
management of drug 
therapy in South Africa
Health care professionals and patients are 
faced with specific challenges that may 
interfere with optimal management of drug 
therapy. Special attention to these challenges 
may further improve drug management in 
older persons. Some of the challenges are 
listed below: 
•    Doctor shopping and involvement of 
multiple professionals, thus no health 
care professional takes responsibility for 
the care of the patient.
•    Poor communication between profes-
sionals.
•    Failure of patients to bring all drugs 
to every consultation, due to a lack of 
awareness of drug interactions.
•    Limited doctor/patient communication 
due to various barriers such as language 
and literacy.
•    Poor patient education regarding the 
illness and need for drug therapy.
•    Use of both generic and trade names 
(patients may assume that they are 
different drugs).
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Table I.  Risk factors for adverse drug events in older patients7
•    Age > 85 years
•    Low body weight or body mass index
•    ≥ 6 concurrent chronic diagnoses
•    Estimated creatinine clearance < 50 ml per minute
•    ≥ 9 medications
•    ≥ 12 doses of medications per day
•    A prior adverse drug reaction
Table II.  Common presentations of adverse drug effects in the elderly15
Adverse effect   Drug group
Confusion   Benzodiazepines, phenothiazines, anticholinergic  
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    often)
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    butyrophenones, anticonvulsants
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    tricyclic antidepressants, antiparkinson agents
Incontinence   Diuretics, prazosin (reduced bladder neck tone),  
    anticholinergic agents (urinary retention and   
    overflow incontinence)
Hypothermia   Phenothiazines, barbiturates, benzodiazepines,  
    tricyclic antidepressants, narcotic analgesics,   
    ethanol
Constipation   Anticholinergic agents, phenothiazines, tricyclic  
    antidepressants, verapamil
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•    Inadequate patient education and 
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•   Visual impairment
•   Impairment of physical function
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In a nutshell 
•    Older persons may need multiple drug therapy for an increased number of chronic 
diseases. 
•    Alterations in pharmacokinetics and pharmacodynamics as well as the presence of 
disease and the use of multiple prescriptions and over-the-counter drugs increase ad-
verse drug reactions. 
•    Substantial inter-patient variability in this age group requires individualisation of drug 
therapy. 
•    Regular review of medication, the use of simple drug regimens, maintenance of good 
records, patient education and ensuring good compliance are important factors in 
providing safe and effective therapy. 
•    Improved outcomes, a lower risk of adverse events, and the management or prevention 
of drug interactions can be achieved by applying basic principles of prescribing.
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The streets are unhealthy
Prostitutes working on the streets have far more health problems than those working in massage parlours, according to a survey of 
sex workers in Bristol, UK. The survey also found serious gaps in the provision of health care for all sex workers, providing greater 
ammunition for those pushing for legalisation of brothels.
Apparently the major factor driving poor health among street sex workers is drug abuse. Only 4 of 71 massage parlour workers used 
heroin compared with 60 out of 71 street workers. The picture was similar for crack cocaine and other injectable drugs.
The health problems seen in greater numbers in street workers include abscesses, deep vein thrombosis, chest infections and hepatitis 
B and C. They were also more likely to suffer from anxiety and depression. Parlour workers experienced half the amount of ill-health 
reported by street workers and were more likely to be screened regularly for sexually transmitted infections.
New Scientist,16 June 2007.
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